TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03449446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FIR
Description: 20 mg tablet administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FIR
Description: 20 mg tablet administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CILO
Description: 30 mg tablet administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CILO
Description: 30 mg tablet administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CILO
Description: 30 mg tablet administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match FIR
Description: Tablet administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match FIR
Description: Tablet administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match FIR
Description: Tablet administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match FIR
Description: Tablet administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match CILO
Description: Tablet administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match CILO
Description: Tablet administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match CILO
Description: Tablet administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match CILO
Description: Tablet administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match SEL
Description: Tablet administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match SEL
Description: Tablet administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match SEL
Description: Tablet administered orally once daily without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match SEL
Description: Tablet administered orally once daily without regard to food
Study: NCT03032679

Intervention type: OTHER
Intervention: Non interventional study
Description: No intervention
Study: NCT00142623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored DVDs
Description: Five DVDs aimed at reducing exposure to ETS
Study: NCT00579995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral N-Acetylcysteine
Description: 600 milligrams (mg)
Study: NCT03055988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol
Description: Fixed Dose Combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fixed Dose Combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Fixed Dose Combination
Study: NCT00082238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable isotopes
Description: Stable isotopes were used to quantify gluconeogenesis GNG, hepatic glucose production (HGP), and protein breakdown.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stable isotopes
Description: Stable isotopes were used to quantify gluconeogenesis GNG, hepatic glucose production (HGP), and protein breakdown.
Study: NCT05310006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise sessions were performed in the morning (07:00 am-12:00 am) under the supervision of at least two fitness instructors in the rehabilitation unit of the nursing home.HSRE and TRE were designed according to the peculiarities of each type of resistance exercise (Chodzko-Zajko et al., 2009). During TRE, participants performed four sets of 8-10 repetitions at 70-75% of the maximal strength. The concentric and eccentric phases were carried out for 2 s. For HSRE, exercises were performed eight times (sets) with 4-5 repetitions at 70-75% of the maximal strength. The concentric phase was performed as fast as possible, and the eccentric phase was carried out for 2 s. Bilateral calf raise was performed using the same load as unilateral knee extension.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise sessions were performed in the morning (07:00 am-12:00 am) under the supervision of at least two fitness instructors in the rehabilitation unit of the nursing home.HSRE and TRE were designed according to the peculiarities of each type of resistance exercise (Chodzko-Zajko et al., 2009). During TRE, participants performed four sets of 8-10 repetitions at 70-75% of the maximal strength. The concentric and eccentric phases were carried out for 2 s. For HSRE, exercises were performed eight times (sets) with 4-5 repetitions at 70-75% of the maximal strength. The concentric phase was performed as fast as possible, and the eccentric phase was carried out for 2 s. Bilateral calf raise was performed using the same load as unilateral knee extension.
Study: NCT00579995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate
Description: 3 milliliters per kilogram per hour (mL/kg/hr) for one hour pre-procedure and infused at 1mL/kg/hr for 6 hours post-procedure
Study: NCT02349867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study: NCT02349867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D CRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RosetteSep
Description: Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by negative-selection techniques (RosetteSep). Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DEPfff
Description: Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by with the ApoStream dielectrophoretic field-flow fractionation (DEPfff) enrichment device. Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
Study: NCT02381184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: receive100 mg of clomiphene citrate (Clomid®; Hoechst Marion Russel, Cairo, Egypt) daily starting on day 3 of spontaneous or progestin induced cycle for 10 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic ovarian drilling (LOD)
Description: Laparoscopy was performed under general anesthesia, using three-puncture technique
Study: NCT02963233

Intervention type: PROCEDURE
Intervention: Closed reduction and percutaneous pinning and immobilization

Intervention type: PROCEDURE
Intervention: Non-operative reduction and immobilization
Study: NCT00862472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DuoTrav APS
Description: DuoTrav APS QD AM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DuoTrav
Description: DuoTrav QD AM
Study: NCT05113667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pharmacist-led Appropriate Acid Suppression Therapy Stewardship Program
Description: Clinical pharmacist provided medication reconciliation and medication review during the hospital stay.
Study: NCT04591249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Participants will 1) receive Fitbit, 2) be enrolled in a secure electronic platform to access Fitbit data, 3) receive 8-week remote counseling by a physical therapist that will include motivational interviewing and creating SMART goals (1 session per week) through a web-based teleconference platform, and 4) receive usual postoperative care directed by their surgeon. The first session will be 45 minutes and sessions 2-8 will be 30 minutes each. During the sessions, participant's confidence in meeting daily step goals will be assessed using a 0-10 scale. If self-reported confidence to meet their goal is \<8, the physical therapist will help participants modify their goal using techniques such as problem-solving, positive statements and affirmations. Progression will be made only if daily steps goals are met for at least 4 out of 7 days a week. If this weekly step goal is not met, a physical therapist will help the participant identify solutions for realistic progression.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Participants will receive postoperative care as determined by their treating surgeon. This includes lifting restrictions, advice to stay active, and oral analgesics as needed. Physical therapy referral will be at the discretion of the surgeon. However, physical therapy is not typically started until 12 weeks after surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Participants will receive postoperative care as determined by their treating surgeon. This includes lifting restrictions, advice to stay active, and oral analgesics as needed. Physical therapy referral will be at the discretion of the surgeon. However, physical therapy is not typically started until 12 weeks after surgery.
Study: NCT03047291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: 30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 30 placebo tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
Study: NCT02578342

Intervention type: DEVICE
Intervention: MRI
Description: Functional Magnetic Resonance Imaging technique measures brain activity by detecting associated changes in blood oxygenation level dependency

Intervention type: DEVICE
Intervention: MRI
Description: Functional Magnetic Resonance Imaging technique measures brain activity by detecting associated changes in blood oxygenation level dependency

Intervention type: DEVICE
Intervention: MRI
Description: Functional Magnetic Resonance Imaging technique measures brain activity by detecting associated changes in blood oxygenation level dependency
Study: NCT02558400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG324 Ophthalmic Solution 0.02%/0.005%
Description: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Netarsudil (AR-13324) Ophthalmic Solution 0.02%
Description: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost Ophthalmic Solution 0.005%
Description: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)
Study: NCT00973882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC4 on day 1 repeated every 3 weeks for a maximum of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m2 on day 1, day 2 and day 3 repeated every 3 weeks for a maximum of 6 cycles
Study: NCT02631733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Sucrosofate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01830582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced MR Imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced MR Imaging
Study: NCT03715218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mothers Touch Program
Description: Mothers Touch Program with bed rest, Relaxation program to reduce stress, massage for mother and infant, gently physical exercise and special dietary program each week.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care Program
Description: Usual care group had advice, support and educational program delivered by midwife, or physicians.
Study: NCT02398955

Intervention type: DEVICE
Intervention: percutaneous coronary intervention
Description: percutaneous coronary angioplasty with implantation of at least one Biomime stent
Study: NCT01995214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Anesthesia maintenance with propofol+remifentanil guided by Narcotrend index monitoring.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthesia maintenance with sevoflurane+remifentanil guided by Narcrotrend index monitoring.
Study: NCT02378701

Intervention type: BEHAVIORAL
Intervention: QUALMS-1 Questionnaire
Description: Participants complete the QUALMS-1 during first treatment visit, and after 4th cycle of treatment or when treatment stops.

Intervention type: BEHAVIORAL
Intervention: FACT-An Questionnaire
Description: Participants complete the FACT-An during first treatment visit, and after 4th cycle of treatment or when treatment stops.
Study: NCT03695679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive computer-based intervention
Description: There are 4 components of the Interactive computer-based intervention(ICBI) which will be delivered in 3 phases:~1. Perceived Susceptibility and Perceived Severity~2. Perceived Benefits and Perceived Barriers~3. Cue to Action~4. Self-Efficacy~In addition, a discussion forum will be created to handle questions from the participants. Also, there will be an email address for enquiries if the participants need any support or if they want to seek further enquiry/ clarification after reading the web-based information.
Study: NCT03879655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTS-270
Description: Administered IT via LP infusion of VTS-270
Study: NCT00142818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 150 mg daily for males; 100 mg daily for females
Study: NCT02785107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M-PAC Group
Description: Participants attended a workshop, completed a worksheet and received a booster phone call follow-up at week four.
Study: NCT01593488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal cytarabine
Description: given intrathecally in induction phase every 15 days until CSF response for up to 7 injections. Then it is given every 4 weeks during consolidation phase while patient awaiting bone marrow transplant. For those patients who are not candidates for a bone marrow transplant, the drug will be given every 3 months for 4 administrations (maintenance therapy)
Study: NCT01326416

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-Leucine and L-arginine
Description: Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g L-Leucine and 9 g of L-arginine), to be distributed during each of the 3 main meals.
Study: NCT00142818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 150 mg daily for males; 100 mg daily for females

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 400 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 400 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg and/or 100-150 mg placebo pills
Study: NCT00606021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Description: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
Study: NCT02752178

Intervention type: OTHER
Intervention: MA
Description: Monoaminergic antidepressant use

Intervention type: OTHER
Intervention: MA
Description: Monoaminergic antidepressant use

Intervention type: OTHER
Intervention: DEP
Description: Depression measured using the Hamilton Depression (HAM-D) questionnaire

Intervention type: OTHER
Intervention: DEP
Description: Depression measured using the Hamilton Depression (HAM-D) questionnaire
Study: NCT01183611

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental recombinant hepatitis B vaccine, HBIG
Description: Experimental 10mcg/0.5 ml recombinant hepatitis B vaccine and 200IU HBIG

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental recombinant hepatitis B vaccine, HBIG
Description: Experimental 10mcg/0.5 ml recombinant hepatitis B vaccine and 200IU HBIG

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator hepatitis B vaccine
Description: Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine，200IU HBIG

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator hepatitis B vaccine
Description: Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine，200IU HBIG

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental recombinant hepatitis B vaccine
Description: Experimental 10mcg/0.5 ml of recombinant hepatitis B vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator recombinant hepatitis B vaccine.
Description: Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator recombinant hepatitis B vaccine
Description: Placebo Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.
Study: NCT00868738

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Subjects will be provided supplemental vitamin D3 (1000 IU) or placebo, given once daily (based on the stratification noted above). Vitamin D/placebo will be provided using a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Subjects will be provided supplemental vitamin D3 (1000 IU) or placebo, given once daily (based on the stratification noted above). Vitamin D/placebo will be provided using a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
Study: NCT02527031

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECMO Insertion on pre hospital setting
Description: ECMO Insertion on pre hospital setting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In Hospital ECMO
Description: ECMO Insertion on in hospital setting for a refractory cardiac arrest
Study: NCT04498949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UP
Description: The unified protocol modules are as follows:~Module 1: Setting the treatment goals and motivation augmentation Module 2: Using psychoeducation to learn the function of emotions and their development Module 3: Mindful (present-focused and non-judgmental) emotional awareness- Core module Module 4: Cognitive flexibility- Core module Module 5: Identifying and countering emotional avoidance behaviors- core module Module 6: Increasing awareness and confronting physical sensations/ interoceptive sensitivity- core module Module 7: Both situational and interoceptive emotion-focused exposures- Core module Module 8: Recognizing accomplishments and looking to the future (relapse prevention)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Diagnostic test. Psychoeducation Supoortive care
Study: NCT03513575

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: no intervention
Description: Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test flavored milk drink without any intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2: tap water gargle
Description: The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 3: 0.2% Chlorhexidine
Description: The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 4: Fluoridated tooth paste
Description: The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 5: Polyol containing gum
Description: The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing as an intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 6: 1% sodium bicarbonate solution
Description: The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.